INTRODUCTION {#SEC1}
============

Single nucleotide polymorphisms (SNPs), the most common type of human genetic variation, play important roles in human complex traits and diseases ([@B1]--[@B3]). Genome-wide association studies (GWAS) identified more than 10 000 SNPs associated with susceptibility of human traits or diseases ([@B4],[@B5]). Most GWAS-detected risk SNPs are located in the genome\'s non-coding regions ([@B6]), indicating that these SNPs mainly exert their functional roles via regulating gene expression. Therefore, understanding SNP regulation of gene expression is essential for interpreting disease related SNPs.

Expression quantitative trait locus (eQTL) analysis, which links variations in gene expression to genotypes, has been demonstrated as a powerful approach to understanding the effects and molecular mechanism of functional SNPs ([@B7]--[@B10]). Previous studies identified eQTLs mainly from lymphoblastoid cell lines and normal human tissues ([@B9],[@B11]--[@B13]). For example, the Genotype-Tissue Expression (GTEx) consortium identified eQTLs from 7051 tissue samples of 44 tissues from 449 donors ([@B13]). Due to the significance of eQTLs, several databases have been developed to collect eQTLs, including the GTEx Portal ([@B13]), ExSNP ([@B14]), seeQTL ([@B15]) and SCAN ([@B16]). However, no database comprehensively provides eQTLs in large number of cancer samples. The majority of eQTLs identified from cancer samples are cancer-specific through a comparison between tumor and normal samples ([@B17]). Therefore, it is necessary to analyze eQTLs from large-scale cancer samples to further understand the functional effects of eQTLs in cancer. Furthermore, the majority of studies and databases neglected *trans*-eQTLs, which are highlighted with significant functions in recent studies ([@B7],[@B18]). Collectively, systematic and large-scale investigations of both *cis*- and *trans*-eQTLs in multiple cancer types would provide the research community with a further understanding of inherited variant effects in tumorigenesis and development.

The Cancer Genome Atlas (TCGA) generated a large amount of omics data, including RNA sequencing, genotype data and clinical survival information from more than 10 000 cancer samples. These data provide a valuable source for eQTL analysis and further integrative analysis across different cancer types.

DATA COLLECTION AND PROCESSING {#SEC2}
==============================

Genotype data collection, imputation and processing {#SEC2-1}
---------------------------------------------------

To comprehensively identify eQTLs across different cancer types, we obtained genotype data from the TCGA data portal (<https://tcga-data.nci.nih.gov/tcga/>), which detected the genotypes using Affymetrix SNP 6.0 array containing 898 620 SNPs. To increase the power for eQTL discovery, we imputed autosomal variants for all samples in each cancer type using IMPUTE2 ([@B19]), with 1000 Genomes Phase 3 ([@B20]) as the reference panel. To improve computation efficiency, we used the two-step procedure of IMPUTE2, which includes pre-phasing, and the imputation of the phased data. After imputation, we used the following criteria to select SNPs ([@B13]): (i) imputation confidence score, INFO ≥ 0.4, (ii) minor allele frequency (MAF) ≥ 5%, (iii) SNP missing rate \<5% for best-guessed genotypes at posterior probability ≥0.9 and (iv) Hardy--Weinberg Equilibrium *P*-value \> 1 × 10^−6^ estimated by Hardy--Weinberg R package ([@B21]) (Figure [1A](#F1){ref-type="fig"}).

![Identification of eQTLs in PancanQTL database. (**A**) Genotyping data collection and processing. (**B**) Covariates analyzed in eQTL mapping. (**C**) Gene expression data collection and processing. (**D**) eQTL analyses of *cis*-eQTLs, *trans*-eQTLs, survival-associated eQTLs and GWAS-related eQTLs.](gkx861fig1){#F1}

Gene expression data collection and processing {#SEC2-2}
----------------------------------------------

The gene expression profiles were obtained from the TCGA data portal (<https://gdc-portal.nci.nih.gov/>), which contains 20 531 genes for each sample. In each cancer type, genes with average expression (RSEM calculated by Expectation-Maximization ([@B22])) of ≥1 were retained. To minimize the effects of outliers on the regression scores, the expression values for each gene across all samples were transformed into a standard normal based on rank ([@B13]) (Figure [1C](#F1){ref-type="fig"}).

Covariates {#SEC2-3}
----------

Previous studies showed that factors affecting global gene expression may reduce the eQTL-identifying power ([@B23],[@B24]). To remove the global effects on gene expression, covariates are usually included in eQTL analyses ([@B9],[@B13]). To remove the effect of population structure on gene expression, we used smartpca in the EIGENSOFT program ([@B25]) to perform principal component (PC) analyses for each cancer type, and selected the top five PCs in genotype data as covariates. To remove the hidden batch effects and other confounders in the expression data, we used PEER software ([@B26]) to select the first 15 PEER factors from expression data as covariates. To remove the potential effects of clinical status on gene expression, age ([@B9]), gender ([@B13]) and tumor stage ([@B17]) were included as additional covariates (Figure [1B](#F1){ref-type="fig"}).

Identification of eQTLs {#SEC2-4}
-----------------------

For each cancer type, the genotype data, expression data and covariates were processed to three N (genotype, expression or covariates) × S (samples) matrix files with matched sample order. The gene location (hg19) was downloaded from Genomic Data Commons (<https://gdc.cancer.gov/>). The SNP location (hg19) was downloaded from dbSNP (<https://www.ncbi.nlm.nih.gov/projects/SNP/>) (v137). eQTL analysis was performed by Matrix eQTL ([@B27]) in linear regression model. SNPs with false discovery rates (FDR) \< 0.05 were defined as eQTLs. *Cis*-eQTLs were defined if the SNP was within 1 Mb from the gene transcriptional start site (TSS) ([@B13]), and *trans*-eQTLs were defined if the SNP was beyond that point (Figure [1D](#F1){ref-type="fig"}).

Survival-associated eQTLs {#SEC2-5}
-------------------------

Many genes are associated with cancer prognoses ([@B28]), and eQTLs may influence the prognosis by altering gene expression. To identify survival-associated eQTLs, we examined the associations between eQTLs and patient overall survival. For each eQTL, samples were classified into three groups: homozygous genotype AA, heterozygous genotype Aa and homozygous genotype aa (A and a represent two alleles of one SNP). The log-rank test was used to examine the differences in survival time, and Kaplan--Meier (KM) curves were plotted to represent the survival time for each group. eQTLs with FDR \< 0.05 were defined as survival-associated eQTLs (Figure [1D](#F1){ref-type="fig"}).

GWAS-related eQTLs {#SEC2-6}
------------------

Risk SNPs identified in GWAS studies were downloaded from the GWAS catalog (<http://www.ebi.ac.uk/gwas/>) ([@B5]). GWAS linkage disequilibrium (LD) regions were extracted from SNAP (<https://personal.broadinstitute.org/plin/snap/ldsearch.php>) ([@B29]) with parameters (SNP dataset: 1000 Genomes; *r^2^* (the square of the Pearson correlation coefficient of linkage disequilibrium) threshold: 0.5; population panel: CEU (Utah Residents with Northern and Western European Ancestry); Distance limit: 500 kb). eQTLs that overlap with GWAS tagSNPs and LD SNPs (*r^2^* ≥ 0.5) were identified as GWAS-related eQTLs.

DATABASE CONTENT AND USAGE {#SEC3}
==========================

Samples in PancanQTL {#SEC3-1}
--------------------

PancanQTL included 9196 tumor samples from 33 cancer types. The sample size of each cancer type ranged from 36 in cholangiocarcinoma (CHOL) to 1092 in breast invasive carcinoma (BRCA) (Table [1](#tbl1){ref-type="table"}). For the genotype data, we obtained on average 4 480 214 SNPs for each cancer type after imputation and quality control, ranging from 2 765 921 for BRCA to 5 245 402 for acute myeloid leukemia (LAML). After removing lowly expressed genes (RSEM \< 1), there were on average 17 814 genes for each cancer type, ranging from 16 758 for uveal melanoma (UVM) to 18 790 for testicular germ cell tumors (TGCT).

###### Summary of eQTLs for each cancer type in PancanQTL

                                      *Cis*     *Trans*                             
  ------ ------ --------- ----------- --------- --------- --------- -------- ------ --------
  ACC    77     17, 562   3 678 145   4610      222       4558      984      60     957
  BLCA   408    18 171    4 242 910   142 562   5573      120 374   9199     1575   3114
  BRCA   1092   17 991    2 765 921   438 476   11 859    317 935   73 124   6013   20 466
  CESC   300    17 975    4 367 017   95 702    4165      84 484    2209     674    971
  CHOL   36     17 767    4 106 282   11        2         11        5011     127    4436
  COAD   286    17 500    4 576 984   164 356   5048      145 461   3085     373    2359
  DLBC   48     17 245    4 945 365   391       15        391       5        3      5
  ESCA   184    18 372    4 563 674   39 358    1603      36 589    425      56     410
  GBM    150    17 650    4 660 522   59 788    1901      55 855    481      55     465
  HNSC   518    17 985    4 302 347   267 797   6502      228 069   9285     1064   7389
  KICH   66     17 212    3 902 792   7264      320       7038      5826     157    4669
  KIRC   527    17 812    4 632 879   521 072   8739      410 720   13 978   943    12 200
  KIRP   290    17 715    4 981 141   186 310   4920      164 159   2712     302    2516
  LAML   123    17 099    5 245 402   70 375    1758      64 696    580      38     397
  LGG    515    17 563    4 688 205   578 617   9177      437 580   21 236   1804   13 084
  LIHC   369    17 816    4 218 042   151 613   5723      128 956   16 675   2230   3963
  LUAD   514    18 190    4 435 432   259 475   6834      220 709   6157     745    4513
  LUSC   500    18 277    3 787 605   204 145   6367      173 856   11 934   1050   10 487
  MESO   87     17 742    4 904 165   16 527    475       16 140    474      43     471
  OV     301    18 137    3 018 011   92 743    7100      74 419    6196     2028   2245
  PAAD   178    18 021    5 099 858   113 810   2468      104 058   1221     110    978
  PCPG   178    17 552    4 836 419   93 679    3203      83 517    1146     241    985
  PRAD   494    17 646    4 887 130   691 299   10 152    514 457   15 730   1105   11 589
  READ   94     17 427    4 653 098   22 788    781       22 114    72       14     72
  SARC   258    18 183    4 156 361   70 201    4194      61 193    5704     1055   4115
  SKCM   103    17 645    4 968 336   15 046    720       14 487    348      45     299
  STAD   415    18 478    4 362 659   161 271   4913      142 709   2470     391    1994
  TGCT   150    18 790    4 927 197   71 832    1959      67 882    653      39     599
  THCA   503    17 277    4 936 390   927 678   10 766    659 323   13 592   745    8908
  THYM   120    17 785    5 036 992   85 627    2090      78 507    436      43     379
  UCEC   176    18 195    5 111 002   25 426    1188      24 721    251      35     248
  UCS    56     18 314    4 036 518   488       25        488       6        2      6
  UVM    80     16 758    4 812 283   26 233    890       25 260    5        4      5

^a^The full names of cancer types are shown in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

eQTLs in PancanQTL {#SEC3-2}
------------------

For each cancer type, the average associations of ∼81 billion SNP-gene pairs were tested for *cis*- and *trans*-eQTL mapping. In *cis*-eQTL analysis, we identified 5 606 570 eQTL-gene pairs in 33 cancer types at a per-tissue FDR \< 0.05, which corresponded to a median *P*-value \< 9.22 × 10^−5^ ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). There were 11 *cis*-eQTLs identified in CHOL, while 659 323 *cis*-eQTLs were identified in thyroid carcinoma (THCA). The number of *cis*-eQTLs was significantly correlated with the number of samples (Spearman correlation *Rs* = 0.93, *P-*value = 2.97 × 10^−15^). The number of *cis*-eQTL regulated genes (egenes) ranged from two in CHOL to 11 859 in BRCA (Table [1](#tbl1){ref-type="table"}). For *trans*-eQTL analysis, we identified 231 210 eQTL-gene pairs in 33 cancer types at a per-tissue FDR \< 0.05, which corresponded to a median *P*-value \< 1.54 × 10^−9^ ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). The number of *trans*-eQTLs ranged from five in lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) and uterine carcinosarcoma (UCS) to 20 466 in BRCA, while the number of egenes ranged from two in UCS to 6013 in BRCA (Table [1](#tbl1){ref-type="table"}). The number of *trans*-QTLs is also significantly correlated with the number of samples (*Rs* = 0.74, *P-*value = 6.84 × 10^−7^).

Among the *cis*- and *trans*-eQTLs, we identified 22 212 eQTLs associated with patient overall survival in the different cancer types at FDR \< 0.05. The number of survival-associated eQTLs ranged from one in UCS to 4330 in THCA. To identify GWAS-related eQTLs, we extracted 28 345 trait/disease-related SNPs from the GWAS catalog and obtained 1 167 961 SNPs located in GWAS LD regions. Among these, 337 131 SNPs are eQTLs in at least one cancer type.

Web design and interface {#SEC3-3}
------------------------

Results were organized into a set of relational MySQL tables ([@B30]), with the website constructed using HTML and PHP. We designed four modules to display *cis*-eQTLs, *trans*-eQTLs, survival-associated eQTLs and GWAS-related eQTLs (Figure [2A](#F2){ref-type="fig"}). Users could browse each eQTL module simply by clicking the corresponding module. On the home page, we designed an advanced search box for a comprehensive query across four modules (Figure [2B](#F2){ref-type="fig"}). For example, the user can select a cancer type (e.g. STAD) and input an SNP ID (e.g. rs2351010), gene symbol (e.g. ERAP2) or genomic region (e.g. chr1:1--1000000) to search eQTLs in four modules. A quick search option is available on each page (top right) to search by SNP ID, gene symbol or genomic region. Users can download *cis*-eQTLs and *trans*-eQTLs for each cancer type from the 'Download' page. The 'Help' page provides information for data collection and processing. PancanQTL welcomes any feedback by email on the 'Contact' page.

![Overview of PancanQTL database. (**A**) Four modules in PancanQTL, including *cis*-eQTLs, *trans*-eQTLs, survival-associated eQTLs and GWAS-related eQTLs. (**B**) Advanced search box in PancanQTL. (**C**) Example of an eQTL boxplot in *cis*-eQTL page. (**D**) Example of a KM plot in survival-eQTL page.](gkx861fig2){#F2}

Data browsing and querying of four modules {#SEC3-4}
------------------------------------------

Using the homepage browser bar or clicking directly on the '*cis/trans*-eQTLs' module, users can enter *cis/trans*-eQTLs page. A table with SNP ID, SNP genomic position, SNP alleles, gene symbol, gene position, beta value (effect size of SNP on gene expression) and eQTL *P*-value are displayed on the *cis/trans*-eQTLs page. When the user selects a specific cancer type or enters a gene or SNP ID, the table will be rebuilt to display the query results. For each record of SNP-gene pairs, a vector diagram of boxplot is provided to display the association between SNP genotypes and gene expression. For example, our analysis showed that *ERAP2* expression in individuals carrying the homozygote rs2351010 aa is significantly higher than that in individuals carrying the homozygote rs2351010 AA and heterozygous rs2351010 Aa (*P*-value = 2.37 × 10^−302^) (Figure [2C](#F2){ref-type="fig"}).

On the survival-eQTLs page, the SNP information and median overall survival time of each genotype are provided. Search boxes are designed for retrieving specific cancer types and SNPs. For each SNP, a vector diagram of KM plot is provided to display the association between SNP genotypes and overall survival. For example, our analysis showed that patients with the rs1824937 aa genotype have worse prognoses than other breast cancer patients (*P*-value = 6.3 × 10^−7^) (Figure [2D](#F2){ref-type="fig"}).

On the GWAS-eQTLs page, the SNP information, regulated gene information and related GWAS traits are displayed. Search boxes are designed for retrieving specific cancer types and SNPs. In addition, users can select a different LD threshold from the dropdown box to prioritize SNPs.

SUMMARY AND FUTURE DIRECTIONS {#SEC4}
=============================

We systematically identified *cis*-eQTLs, *trans*-eQTLs, survival-associated eQTLs and GWAS-related eQTLs in 33 cancer types. We constructed a user-friendly database, PancanQTL, for users to query, browse and download eQTLs. Millions of vector diagrams of eQTL box plots and KM plots are provided. PancanQTL could serve as an important resource for human cancer genetics and provide opportunities to bridge the knowledge gap from variants in sequence to phenotypes. PancanQTL could also contribute to understanding the effects of inherited variants in tumorigenesis and development. Cancer genomics is a rapidly developing field ([@B31]), and we expect that the number of cancer samples with genotype and gene expression profiles will increase dramatically. We will update PancanQTL to include more cancer samples and will maintain it as a useful resource for the research community. Previous studies demonstrated the complicated mechanisms for regulating gene expression by eQTLs, including altering RNA sequence, RNA structure, transcription factor binding, miRNA binding, methylation and histone modification ([@B32],[@B33]). It will be very interesting to further investigate the regulating mechanisms of eQTLs through integrative analysis if multi-dimensional data are available.

Supplementary Material
======================
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Click here for additional data file.
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